The Utility of IL-17 Inhibitors in Neutrophilic Dermatoses: A Systematic Review

Abstract

Keywords

neutrophilic dermatosis pyoderma gangrenosum Behçet’s disease IL-17 inhibitors secukinumab

Get full access to this article

View all access options for this article.

References

Nelson

CA.

Stephen

Ashchyan

HJ.

James

WD.

Micheletti

RG.

Rosenbach

. Neutrophilic dermatoses. J Am Acad Dermatol. 2018;79(6):987-1006.doi:10.1016/j.jaad.2017.11.064

Di Scala

Bettiol

Cojan

RD.

Finocchi

Silvestri

Emmi

. Efficacy of the anti-IL 17 secukinumab in refractory Behçet’s syndrome: a preliminary study. J Autoimmun. 2019;97:108-113.doi:10.1016/j.jaut.2018.09.002

30213443

Puig

. Paradoxical reactions: anti-tumor necrosis factor alpha agents, ustekinumab, Secukinumab, ixekizumab, and others. Curr Probl Dermatol. 2018;53:49-63.doi:10.1159/000479475

29131037

States

O’Brien

Rai

et al. Pyoderma gangrenosum in inflammatory bowel disease: a systematic review and meta-analysis. Dig Dis Sci. 2020;65(9):2675-2685.doi:10.1007/s10620-019-05999-4

31925675

Murad

MH.

Sultan

Haffar

Bazerbachi

. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23(2):60-63.doi:10.1136/bmjebm-2017-110853

29420178

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.11 MB

0.15 MB

0.01 MB